Aquatic Capital Management LLC Genmab A/S Transaction History

Aquatic Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.13 - $30.27 $693,588 - $835,452	27,600 New	27,600 $693,000
Q4 2023 Feb 14, 2024	BUY	$27.94 - $35.44 $329,692 - $418,192	11,800 Added 99.16%	23,700 $755,000
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $109,337 - $130,944	3,100 Added 35.23%	11,900 $420,000
Q2 2023 Aug 14, 2023	BUY	$37.4 - $42.94 $329,120 - $377,872	8,800 New	8,800 $334,000
Q2 2022 Aug 15, 2022	SELL	$26.83 - $38.57 $2,683 - $3,857	-100 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$35.87 - $47.12 $3,586 - $4,712	100 New	100 $4,000

236

49.7M

6.8K

27.6K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.3B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.